Kim Mi-Ryoung, Yun Ji Young, Jeon Beomseok, Lim Yong Hoon, Kim Kyung Ran, Yang Hui-Jun, Paek Sun Ha
Department of Neurosurgery, Movement Disorder Center and Neuroscience Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Department of Neurology, Ewha Womans University Mokdong Hospital and Ewha Womans University School of Medicine, Seoul, Republic of Korea.
Parkinsonism Relat Disord. 2016 Feb;23:91-4. doi: 10.1016/j.parkreldis.2015.11.010. Epub 2015 Nov 19.
Many patients with advanced Parkinson's disease (PD) are reluctant to undergo the subthalamic nucleus deep brain stimulation (STN-DBS) when surgery is warranted. Reasons for this reluctance have not been examined. We undertook to establish the rate and causes of this reluctance for STN-DBS in patients with advanced PD.
A reluctant group was defined as patients who were hesitant to undergo DBS. Clinical information included age, onset age, disease duration, the Unified Parkinson Disease Rating Scale, Hoehn and Yahr stage and levodopa equivalent dose when they were evaluated with a view to consider surgery.
We enrolled 186 patients who underwent STN-DBS. 84 patients (45%) belonged to the reluctant group. Between the reluctant and the non-reluctant, there were no differences in preoperative characteristics. Main reasons for hesitation were fear of complications (74%) and economic burden (50%). The main reasons that they finally underwent the DBS were confidence in the doctor's decision (80%) and encouragement from their family (36%).
Building trust between patients and physicians is an important factor in guiding patients to undergo this treatment. To reduce the reluctance to undergo DBS at the appropriate time, we need to find effective ways of reducing their psychological and economic burden.
许多晚期帕金森病(PD)患者在有手术指征时不愿接受丘脑底核深部脑刺激(STN-DBS)治疗。这种不愿接受治疗的原因尚未得到研究。我们旨在确定晚期PD患者中这种对STN-DBS治疗不愿接受的发生率及原因。
将不愿接受治疗的患者定义为对接受DBS治疗犹豫不决的患者。临床信息包括年龄、发病年龄、病程、统一帕金森病评定量表、Hoehn和Yahr分期以及在评估是否考虑手术时的左旋多巴等效剂量。
我们纳入了186例行STN-DBS治疗的患者。84例患者(45%)属于不愿接受治疗组。在不愿接受治疗组和非不愿接受治疗组之间,术前特征无差异。犹豫的主要原因是害怕并发症(74%)和经济负担(50%)。他们最终接受DBS治疗的主要原因是对医生决定的信任(80%)和家人的鼓励(36%)。
在患者和医生之间建立信任是引导患者接受这种治疗的一个重要因素。为了减少在适当时候对接受DBS治疗的不情愿,我们需要找到减轻他们心理和经济负担的有效方法。